Pfizer's Varenicline NDA For Smoking Cessation Includes Comparison To GSK’s Zyban

In Phase III studies, 44% of varenicline patients quit smoking by the end of a 12-week treatment period, compared to 30% of patients on GlaxoSmithKline’s Zyban, Pfizer reports.